Gerald Baker Financial Group LLC Makes New $8.22 Million Investment in Eli Lilly and Company $LLY

Gerald Baker Financial Group LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 1st quarter, HoldingsChannel.com reports. The fund acquired 8,934 shares of the company’s stock, valued at approximately $8,217,000. Eli Lilly and Company accounts for 2.8% of Gerald Baker Financial Group LLC’s portfolio, making the stock its 9th biggest position.

A number of other large investors have also made changes to their positions in LLY. Norges Bank bought a new position in Eli Lilly and Company during the fourth quarter valued at about $12,976,634,000. J. Stern & Co. LLP lifted its position in shares of Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock worth $4,047,245,000 after acquiring an additional 4,038,502 shares during the period. Cardano Risk Management B.V. lifted its position in shares of Eli Lilly and Company by 876.1% in the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock worth $2,552,419,000 after acquiring an additional 2,131,734 shares during the period. Fifth Third Bancorp grew its holdings in shares of Eli Lilly and Company by 321.3% during the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after purchasing an additional 1,497,423 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Eli Lilly and Company by 10.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after purchasing an additional 1,432,069 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LLY. Bank of America upped their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Sanford C. Bernstein lifted their price target on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research note on Tuesday. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Cantor Fitzgerald increased their price objective on shares of Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a research note on Monday, July 6th. Finally, Citigroup raised their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,283.64.

Eli Lilly and Company Stock Up 1.4%

Shares of NYSE LLY opened at $1,172.50 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The business has a fifty day moving average of $1,114.27 and a two-hundred day moving average of $1,035.81. The stock has a market cap of $1.10 trillion, a PE ratio of 41.65, a PEG ratio of 1.45 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 34.55 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s acquisition of AtaiBeckley strengthens its neuroscience pipeline and adds exposure to treatment-resistant depression and other mental health markets. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
• Positive Sentiment: Several Wall Street notes also turned more bullish on Lilly, with UBS and other firms raising price targets and pointing to continued momentum in Lilly’s GLP-1 and broader pipeline. Eli Lilly Likely to See More Momentum in GLP-1 Pipeline, UBS Says
• Neutral Sentiment: The acquisition comes amid mixed competitive headlines in obesity drugs, including Novo Nordisk’s oral Wegovy approval in Europe, which highlights the rivalry in Lilly’s core growth areas. Novo Nordisk Stock Rises After Wegovy Pill Captured 89% of U.S. Prescriptions
• Negative Sentiment: Some commentary suggests Lilly is paying a rich price for a still-early-stage psychedelic asset, which may raise questions about clinical risk and return on investment if the programs do not deliver. Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.